Cianna Medica (Aliso Viejo, CA) a brachytherapy medical device company focused on women’s health and dedicated to the innovative treatment of early-stage breast cancer closed a $9M Series A financing. Participants include BioLucent, Fog City Fund and Windamere Venture Partners.

Vaccinex  (Rochester, NY) a research and development stage antibody platform company focused on oncology and inflammation closed a $25M Series B financing. Participants include Teva Pharmaceuticals, Pan Atlantic Bank & Trust, Biocon and Toronto Investment Group.

Endotis Pharma (France) a specialty discovery and development company developing small glycol drugs for thrombosis and oncology closed a $36.59M Series B financing. Participants include Wellcome Trust, Endeavour vision, NIF SMBC Ventures and Sofinnova Partners.

Calisotga Pharma (Seattle, WA) a biopharmaceutical company developing multiple compounds selectively targeting the PI3K pathway, a pathway known to be involved in certain cancers and inflammatory diseases closed a $26.2M Series A financing. Participants include Frazier Healthcare Venture, Alta Partners, Three Arch Partners, Amgen Ventures and Lilly Ventures.

AmpliMed (Tucson, AZ) a clinical-stage pharmaceutical company with Phase II lead compounds for malignant melanoma and pancreatic cancer closed on $5M traunche of a $22M Series C financing. Participants include BioMed Venture Partners, Biotech Insight Ventures, Solstice Capital and Valley Ventures.

Endocyte (West Lafayette, IN) developer of folate-targeted based therapeutics for the treatment of renal cell carcinoma, ovarian, endometrial and nscl cancer raised $15M in a Series C financing. Participants included Sanderling Ventures, Burrill & Company, Triathlon Medical Ventures, Blue Chip Venture Company, American Bailey Ventures and CID Capital.

ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases and oncology with lead indications for inflammatory bowel disease and multiple sclerosis, closed a $29.9M Series D finanicing. The deal was led by the Glaxo Group Ltd. and was joined by Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.

Tragara (San Diego, CA) a pharmaceutical company developing therapies for the treatment of lung cancer and inflammatory diseases closed a $40M Series A round. The financing was led by Domain Associates, ProQuest Investments, Morgenthaler Ventures, Oxford Bioscience Partners and Mitsubishi International Corporation.

Spaltudaq (Seattle, WA) is focused on developing tumor-specific therapeutic antibodies for the treatment of cancer and infectious disease raised $29M in a Series B financing. The round was led by Arch Venture Partners and was joined by Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital and Alexandria Equities.

VentiRx Pharmaceuticals (Seattle, WA) a biopharmaceutical company focused on the development of medicines for the treatment of cancer and infectious, respiratory and autoimmune diseases, raised a $26.6M Series A round. The deal was led by Frazier Healthcare Ventures, ARCH Venture Partners and Domain Associates.